最新研报
共 12,377 份研报 · 国内 7,621 · 国外 4,009 · 全库按发布时间排序
奥普特(688686.SH):26年第三季度净利润超预期,毛利率虽不及预期但看好27年AI检测
OPT Machine Vision (688686.SS): 3Q26 Earnings Strong Beat Despite GPM Miss, Upbeat on AI Inspection for 2027
花旗·2026-10-27·14 页·科创板
RELX PLC(REL.L):维持展望;缺乏近期催化剂
RELX PLC (REL.L): Outlook maintained; lack of near-term catalysts
花旗·2026-10-27·13 页·其它
Orange(ORAN.PA):第三季度业绩强劲,EBITDAaL指引上调
花旗·2026-10-27·11 页·其它
DigitalOcean Holdings(DOCN.N)26财年三季报前瞻:在极具吸引力的风险回报比下亮点颇多
DigitalOcean Holdings, Inc. (DOCN.N) 3Q26E Preview: Plenty to Like Against Compelling Risk/Reward
花旗·2026-10-27·16 页·美股
捍卫股价:217暴跌违背逻辑的七大理由
ArriVent BioPharma Inc. (AVBP.O): Defending Stock. 7 Reasons Why The '217 Selloff Defies Logic.
花旗·2026-10-27·12 页·美股
argenx(ARGX.O)2026年三季报回顾与模型更新:12月聚焦Empasiprubart治疗MMN的数据读出;目标价调整至1,232美元/股
argenx (ARGX.O) 3Q26 Recap & Model Update: All Eyes on Empasiprubart MMN Readout in December; TP to $1,232/shr
花旗·2026-10-27·15 页·美股
中国医疗健康:III期阳性数据验证CLDN18.2 ADC;Sone-Ve在患者广度上具差异化优势,IBI343在疗效深度上领先
China Healthcare: Positive Ph3 data validate CLDN18.2 ADCs; Sone-Ve differentiates in patient breadth, IBI343 leads on efficacy depth
高盛·2026-10-27·10 页·医药生物
中国新能源汽车周度图表集:2026年第43周——比亚迪闪充车型上市带动周度订单环比增长9%,碳酸锂价格周环比下跌8%
CHINA NEW ENERGY VEHICLE WEEKLY CHARTBOOK — 2026 Week 43 - Weekly order +9%/-28% wow/yoy driven by BYD flash-charging model launches, LCE price -8% wow
北京高华证券·2026-10-27·10 页·交运设备
中国的科技攻关:支持产出,减少就业
China's High-Tech Push: Support for Output, Less for Employment
北京高华证券·2026-10-27·14 页·中国经济
中国地产周报:第43周周报——市场活动略有放缓;出台新的城市更新政策
CHINA PROPERTY WEEKLY WRAP Week 43 Wrap - Market activities softened slightly; new urban renewal policies launched
北京高华证券·2026-10-27·14 页·房地产
中国:9月工业利润持平,营业收入环比小幅下滑;10月PMI前瞻
China: Industrial profits flat in September while revenue edged down sequentially; October PMIs preview
高盛·2026-10-27·6 页·中国经济
智飞生物(300122.SZ):财报点评:26年第三季度业绩超预期且经营现金流改善;目标价上调至19元,维持买入
Zhifei (300122.SZ): Earnings review: 3Q26 results beat with OCF improving; TP up to Rmb19; Buy
北京高华证券·2026-10-27·7 页·创业板
高盛-英维克(002837.SZ)初评:26年第三季度销售额符合高盛预期,净利润逊于预期;合同负债与存货创新高预示未来收入加速确认;买入
Shenzhen Envicool Technology (002837.SZ) First Take: 3Q26 sales inline with GSe, NP miss; Record contract liabilities and inventories point to accelerating revenue bookings ahead; Buy
高盛·2026-10-27·10 页·A股
怡合达(301029.SZ):受益于电子与半导体业务敞口,26年第三季度业绩超预期
Yiheda Automation (301029.SZ): 3Q26 beat led by electronics and semiconductor exposure; Buy
北京高华证券·2026-10-27·9 页·创业板
双环传动(002472.SZ):2026年第三季度业绩符合预期,汽车零部件业务跑赢行业,市场更关注AI机器人齿轮业务
Shuanghuan Driveline (002472.SZ): 3Q26 in line; more focus on AI robotics gears with auto components outperforming industry
高盛·2026-10-27·8 页·A股
诺华(NOVN.S):2026年三季度初步点评:成本控制持续驱动盈利增长,指引上调暗示核心业务存在约2%的上行空间
Novartis (NOVN.S): 3Q26 First take: Cost control continues to drive earnings momentum, guidance upgrade suggests 2% upside risk to Core Operating Profit
高盛·2026-10-27·10 页·其它
美国:高盛经济指标更新
USA: GS Economic Indicators Update
高盛·2026-10-27·12 页·海外经济
晶合集成(688249.SS):2026年四季度指引符合季节性,三季度营业利润优于预期;维持中性
Nexchip (688249.SS): 4Q26 guidance meet seasonality, 3Q26 OP income better than expected; Neutral
高盛·2026-10-27·9 页·科创板
汇丰控股(0005.HK/HSBA.L):2026年三季度初评:营收偏弱但被较低减值抵消,整体符合预期;宣布最高10亿美元回购
HSBC (0005.HK/HSBA.L): 3Q26 First Take: Inline with softer revenues offset by lower impairments; up to $1bn buyback announced
高盛·2026-10-27·9 页·港股
国瓷材料(300285.SZ)财报点评:26年第三季度营收超预期但受利润率走弱及一次性因素拖累;AI材料出货量将于第四季度启动;中性
Sinocera Functional Material (300285.SZ) Earnings Review: 3Q26 revenue beat tempered by softer margins and one-offs; AI materials shipments set to begin in 4Q; Neutral
北京高华证券·2026-10-27·10 页·创业板
显示 2161 - 2180 条,共 12,377 条